Protagonist Therapeutics

Shares of Protagonist Therapeutics rose to a new all-time high of $155.01, giving it a market capitalization of about $10 billion after gaining 175.66% last year. For Q2 2026 the company reported GAAP earnings per share of $2.29 and license and collaboration revenue of $213 million, of which $200 million came from a Takeda opt-out payment. Several analysts raised their ratings and price targets (including Goldman Sachs $186, Citizens $165), while InvestingPro rates the stock as overvalued relative to fair value. » More on de.investing.com

Protagonist Therapeutics’ stock hit an all-time high of $141.79 and is currently trading at $143.26, implying a market capitalization of about $9.06 billion. The share price is up 155.18% year over year, 61% year-to-date and 69% over the past six months. Data show the stock near its 52‑week high and an overbought RSI; InvestingPro classifies the stock as overvalued. Several analysts raised price targets (including Citizens $165, Truist $145), and the company reported cash and equivalents of $620 million as of March 31, 2026, sufficient through expected 2028. » More on de.investing.com

Protagonist Therapeutics has been highlighted among billionaire Tom Steyer’s top stock picks and remains a long‑held position for Farallon Capital. The company recently secured FDA approval and commercial launch of Icotyde for moderate‑to‑severe plaque psoriasis, triggering a $50 million milestone payment and leaving $580 million in potential future milestones. Icotyde, developed with Johnson & Johnson, is the only once‑daily oral IL‑23R peptide on the market, and Protagonist will earn high‑margin royalties while J&J handles global commercialization. » More on finance.yahoo.com